| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 氧氟草苷D; Oxytroflavoside D | CFN95491 | 1391144-83-4 | C28H30O15 = 606.5 | 10mg | QQ客服：2159513211 |
| 氧氟草苷B; Oxytroflavoside B | CFN95490 | 1391144-81-2 | C34H40O19 = 752.7 | 10mg | QQ客服：1457312923 |
| 氧氟草苷F; Oxytroflavoside F | CFN95489 | 1391144-85-6 | C28H32O15 = 608.6 | 5mg | QQ客服：2159513211 |
| 异鼠李素-3,5-O-二葡萄糖苷; Isorhamnetin 3,5-O-diglucoside | CFN95488 | 2035413-03-5 | C28H32O17 = 640.6 | 10mg | QQ客服：2159513211 |
| 山奈酚 3,5-双葡萄糖苷; Kaempferol 3,5-O-diglucoside | CFN95487 | 205103-97-5 | C27H30O16 = 610.5 | 10mg | QQ客服：2056216494 |
| 槲皮素 3,5-双葡萄糖苷; Quercetin 3,5-O-diglucoside | CFN95486 | 206257-35-4 | C27H30O17 = 626.5 | 10mg | QQ客服：215959384 |
| 6-甲氧基梣酮; 6-Methoxyfraxinellone | CFN95485 | N/A | C15H18O4 = 262.3 | 10mg | QQ客服：1413575084 |
| Giganteone C; Giganteone C | CFN95484 | 1071223-56-7 | C42H50O9 = 698.9 | 10mg | QQ客服：3257982914 |
| Maingayone B; Maingayone B | CFN95483 | 1071223-57-8 | C42H52O8 = 684.9 | 20mg | QQ客服：2056216494 |
| Kihadanin D; Kihadanin D | CFN95482 | 2770024-83-2 | C27H32O9 = 500.6 | 5mg | QQ客服：2159513211 |
| Giganteone A; Giganteone A | CFN95481 | 460337-13-7 | C42H50O10 = 714.9 | 5mg | QQ客服：215959384 |
| Cagayanin; Cagayanin | CFN95480 | 99096-51-2 | C42H50O10 = 714.9 | 20mg | QQ客服：1413575084 |
| Maingayone; Maingayone | CFN95479 | 271585-66-1 | C42H52O9 = 700.9 | 10mg | QQ客服：3257982914 |
| 8-表马钱子苷; 8-Epiloganin | CFN95478 | 79172-04-6 | C17H26O10 = 390.4 | 20mg | QQ客服：1413575084 |
| 马拉巴酮A; Malabaricone A | CFN95477 | 63335-23-9 | C21H26O3 = 326.4 | 10mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)